NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease.
When there is damage to the nervous system a scar forms. The scar forms in response to acute damage, such as spinal cord injury (SCI), or in chronic diseases, such as multiple sclerosis (MS) and Alzheimer’s disease (AD). Scars contain molecules called chondroitin sulfate proteoglycans (CSPGs). CSPGs bind to a cellular receptor called protein tyrosine phosphatase sigma (PTPσ). This interaction of CSPGs and PTPσ initially helps to contain damage, but in the long term it interferes with repair of the nervous system.
NervGen’s lead drug candidate, NVG-291, relieves the inhibitory effects of CSPGs and thus enables nervous system repair. NVG-291 is a first-in-class experimental drug administered by injection under the skin. In animal studies, this therapeutic approach promoted nervous system repair and enhanced recovery of functions such as walking, bladder control, vision, and memory.
NVG-291 is currently in a Phase 1 clinical trial in healthy volunteers to evaluate safety, tolerability, and metabolism.
After completing our Phase 1 clinical trial, we plan to study the effectiveness and safety of NVG-291 initially in people with spinal cord injury, Alzheimer’s disease and multiple sclerosis.
Read More …